In fact, recent studies with combination therapy using BRAF and MEK inhibitors and immunotherapies indicate rates of 5-year progression free survival and overall survival as high as 30–50% for metastatic melanoma patients whose tumors harbor a gain-of-function mutation in the BRAF gene [1–6]. This evidence concerns the gene BRAF and metastatic melanoma.